Reni Benjamin

Raymond James: Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger

Analysts Remain Encouraged By Bellicum Pharma's Progress

Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics

Analysts Remain Encouraged By Bellicum Pharma's Progress

Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics

Raymond James: Fate Therapeutics & Ocata Expected To Beat Market

3 Stocks That Made A Big Impact At ASCO

Raymond James: Fate Therapeutics & Ocata Expected To Beat Market

3 Stocks That Made A Big Impact At ASCO

H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE

Wainwright Sees TG Therapeutics As Take-Out Target

Reni Benjamin Recent News

UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside

H.C. Wainwright & Co. Sees Significant Upside Ahead For Spectrum Pharmaceuticals

H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued

UPDATE: H.C. Wainwright & Co. Initiates Coverage on GenVec as Overlooked Key Innovator

UPDATE: H.C. Wainwright & Co. Initiates Coverage on Agenus Following 4-Antibody Acquisition

UPDATE: H.C. Wainwright Initiates Coverage on Spectrum Pharmaceuticals on EPS Valuation Methodology

UPDATE: H.C. Wainwright Initiates Coverage on Keryx Biopharmaceuticals on Discounted Revenues, EPS Valuation Methodology

UPDATE: Burrill Institutional Research Downgrades Sarepta Therapeutics on Valuation

Aeterna Zentaris Inc. (AEZS) Going Strong